2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-B0182R
    Carmofur (Standard)
    		Inhibitor
    Carmofur (Standard) is the analytical standard of Carmofur. This product is intended for research and analytical applications. Carmofur (HCFU) is a rat recombinant acid ceramidase inhibitor with an IC50 of 29 nM. Carmofur is also a protease inhibitor of SARS-CoV-2 main protease (Mpro), fatty acid amide hydrolase (FAAH) and N-acylethanolamine acid amidase (NAAA). Carmofur has anti-cancer, anti-inflammatory and anti-virus activities, and can be used for the study of COVID-19 and acute lung injury (ALI).
    Carmofur (Standard)
  • HY-100304AR
    KW-8232 (Standard)
    		Inhibitor
    KW-8232 (Standard) is the analytical standard of KW-8232 (HY-100304A). This product is intended for research and analytical applications. KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.
    KW-8232 (Standard)
  • HY-100229R
    Aloxistatin (Standard)
    		Inhibitor
    Aloxistatin (Standard) is the analytical standard of Aloxistatin. This product is intended for research and analytical applications. Aloxistatin (E64d) is a cell-permeable and irreversible broad-spectrum cysteine protease inhibitor. Aloxistatin (E64d) exhibits entry-blocking effect for MERS-CoV.
    Aloxistatin (Standard)
  • HY-173485
    SARS-CoV-2 Mpro-IN-41
    		Inhibitor
    SARS-CoV-2 Mpro-IN-41 (Compound 7e) is an orally active inhibitor of COX-2 and SARS-CoV-2 M pro (IC50 values are 9.66 μM and 13.24 μM, respectively). SARS-CoV-2 Mpro-IN-41 also has a certain inhibitory activity against COX-1 (IC50: 46.11 μM). SARS-CoV-2 Mpro-IN-41 can significantly inhibit the expression of inflammatory-related cytokines (such as TNF-α, IL-6, IL-1β) and exert anti-inflammatory effects. SARS-CoV-2 Mpro-IN-41 exerts anti-inflammatory and antiviral effects by selectively inhibiting COX-2 and SARS-CoV-2 M pro. SARS-CoV-2 Mpro-IN-41 can be used for anti-inflammatory and anti-coronavirus research.
    SARS-CoV-2 Mpro-IN-41
  • HY-16762R
    Artefenomel (Standard)
    		Inhibitor
    Artefenomel (Standard) is the analytical standard of Artefenomel. This product is intended for research and analytical applications. Artefenomel (OZ439) is an orally active, synthetic anti-malarial compound containing an artemisinin pharmacophore with a mechanism of action similar to that of artemisinin. Artefenomel has antiviral activity against SARS-CoV-2.
    Artefenomel (Standard)
  • HY-W749691
    (S)-Velpatasvir-13C,d3
    		Inhibitor
    (S)-Velpatasvir-13C,d3 ((S)-GS-5816-13C,d3) is 13C labeled Velpatasvir. Velpatasvir (VEL, GS-5816) is a novel pan-genotypic hepatitis C virus (HCV) nonstructural protein 5A (NS5A) inhibitor with activity against genotype 1 (GT1) to GT6 HCV replicons. Velpatasvir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 2.16 μM.
    (S)-Velpatasvir-<sup>13</sup>C,d<sub>3</sub>
  • HY-164868
    SARS-CoV-2-IN-106
    		Inhibitor
    SARS-CoV-2-IN-106 (compound 19) is a SARS-CoV-2 papain-like protease inhibitor with the IC50 values of 0.44 μM and 0.18 μM for PLpro enzymatic and viral replication ,respectively.
    SARS-CoV-2-IN-106
  • HY-169222S
    RORγ/DHODH-IN-2
    		Inhibitor
    RORγ/DHODH-IN-2 (Compound 1311) is an orally active dual inhibitor of RORγ/DHODH with IC50 values of 11.9 nM and 90 nM, respectively. RORγ/DHODH-IN-2 exhibits antiviral activity by inhibiting the activity of SARS-CoV-2, HCMV, HAdV5, and MPXV, with IC50 values of 27 nM, 20 nM, 9.1 nM, and 1.8 nM, respectively.
    RORγ/DHODH-IN-2
  • HY-180369
    SIMR-2418
    		Inhibitor
    SIMR-2418 is an effective inhibitor of the main protease (Mpro) of SARS-CoV-2, with an IC50 value of 20.7 μM. SIMR-2418 can be used for research on SARS-CoV-2 virus infection.
    SIMR-2418
  • HY-W012531R
    2-Hydroxycinnamic acid (Standard)
    		Inhibitor
    2-Hydroxycinnamic acid (Standard) is the analytical standard of 2-Hydroxycinnamic acid. This product is intended for research and analytical applications. 2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against Staphylococcus aureus and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC50 of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity.
    2-Hydroxycinnamic acid (Standard)
  • HY-157144
    SARS-CoV-2-IN-68
    		Inhibitor
    SARS-CoV-2-IN-68 (compound 6C) is a covalent SARS-CoV-2 PLpro/Mpro inhibitor with potent antiviral activities. SARS-CoV-2-IN-68 binds to Zn-finger domain of PLpro.
    SARS-CoV-2-IN-68
  • HY-124654
    SS148
    		Inhibitor
    SS148 is a dual inhibitor of nsp14/nsp16 MTase. SS148 significant inhibits nsp10–nsp16 with an IC50 of 1.2 μM.
    SS148
  • HY-W012531S2
    2-Hydroxycinnamic acid-d4
    		Inhibitor
    2-Hydroxycinnamic acid-d4 is deuterium labeled 2-Hydroxycinnamic acid. 2-Hydroxycinnamic acid is a phenolic acid with antimicrobial and antioxidant properties. 2-Hydroxycinnamic acid has antimicrobial activity against Staphylococcus aureus and is not susceptible to drug resistance. 2-Hydroxycinnamic acid shows inhibitory effects on infection of HIV/SARS-CoV S pseudovirus with an IC50 of 0.3 mM. In addition, 2-Hydroxycinnamic acid has neuroprotective and antitumor activity.
    2-Hydroxycinnamic acid-d<sub>4</sub>
  • HY-161837
    SARS-CoV-2 Mpro-IN-24
    		Inhibitor
    SARS-CoV-2 Mpro-IN-24 (Compound X77) is a inhibitor of SARS-CoV-2 Mpro (IC50=2.8 μM) and also a non-covalent inhibitor of SARS-CoV Mpro (IC50=3.4 μM).
    SARS-CoV-2 Mpro-IN-24
  • HY-163627
    SARS-CoV-2 Mpro-IN-19
    		Inhibitor
    SARS-CoV-2 Mpro-IN-19 (compound MPI94) is a SARS-CoV-2 MPro inhibitor with the IC50 of 0.096 μM. SARS-CoV-2 Mpro-IN-19 can be used for study of COVID-19.
    SARS-CoV-2 Mpro-IN-19
  • HY-168917
    9-Aminominocycline
    		Inhibitor
    9-Aminominocycline (9-AMN) is the inhibitor for SARS-CoV-2 papain-like protease (SARS-CoV-2 PLpro), inhibits its deubiquitination (DUB) activity and protease activity with IC50 of 4.55 µM and 4.15 µM. 9-Aminominocycline inhibits the SARS-CoV variants Delta and Omicron replication in Calu-3 cell with IC50 of 1.04 µM and 2.35 µM.
    9-Aminominocycline
  • HY-10238R
    Danoprevir (Standard)
    		Inhibitor
    Danoprevir (Standard) is the analytical standard of Danoprevir (HY-10238). This product is intended for research and analytical applications. Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC50 of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC50 higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC50s=0.2-0.4 nM) as well as 2b and 3a (IC50s=1.6, 3.5 nM). Danoprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 0.05 μM.
    Danoprevir (Standard)
  • HY-170886
    SARS-CoV-2 Mpro-IN-36
    		Inhibitor
    SARS-CoV-2 Mpro-IN-36 (Compound 6d) is an inhibitor of SARS-CoV-2 Mpro with an IC50 of 110 nM. SARS-CoV-2 Mpro-IN-36 exhibits antiviral activity with an EC50 of 1.6 μM.
    SARS-CoV-2 Mpro-IN-36
  • HY-174251
    (±)-Tuaimenal A
    		Inhibitor
    (±)-Tuaimenal A ((+)-1) is a secondary metabolite and a derivative of Sesamol (HY-N1417). (±)-Tuaimenal A has potent inhibitory activity against SARS-CoV-2 3CLpro with an IC50 of 33.3  μM. (±)-Tuaimenal A can be used for SARS-CoV-2 infection research.
    (±)-Tuaimenal A
  • HY-163908
    SARS-CoV-2-IN-94
    		Inhibitor
    SARS-CoV-2-IN-94 (Compound 6) exhibits antiviral activity against COVID-19 virus by targeting 6VSB protein.
    SARS-CoV-2-IN-94
Cat. No. Product Name / Synonyms Species Source